Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Comparative outcomes of CAR-T therapy in elderly (≥70 Years) versus younger (70 Years) patients with relapsed/refractory multiple myeloma: A real-world propensity-matched cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

FKFayaz KhanRBRenu Bhargavi BoyapatiZAZuhair Alam

Discussion

Loading...

Member takes

Overview

Cohort study shows similar outcomes for CAR-T therapy in elderly and younger patients with multiple myeloma, indicating safety across age groups.

Key Points

  • Elderly patients experienced comparable rates of neurotoxicity and fatigue after CAR-T therapy, with no significant differences noted.
  • Neutropenia rates were similar, indicating that CAR-T is a viable option for older adults without additional risks.
  • Assessment of infections, including pneumonia and septic shock, showed no significant discrepancy between age cohorts.
  • Findings support the safety of CAR-T therapy for elderly patients with multiple myeloma in real-world applications.

Cite This Study

Khan et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7echttps://doi.org/10.1182/blood-2025-2212
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact of age on outcomes of CAR-T cell therapy in multiple myeloma, DLBCL, and follicular lymphoma: A real-world multi-center propensity-matched analysis2025
  2. 2Age-related differences in clinical outcomes among hospitalized recipients of CAR-T cell therapy: A national readmission database analysis2025
  3. 3Safety and efficacy of BCMA directed CAR-T therapy in older patients (Aged ≥ 75) with relapsed or refractory multiple myeloma (RRMM)2025 · 1 citations
  4. 4Real-world comparative outcomes of CAR-T cell therapy versus pomalidomide-based regimens in relapsed/refractory multiple myeloma: A propensity-matched cohort study2025
  5. 5CAR T-cell therapy outcomes in adolescent and young adult patients with non-Hodgkin lymphoma2025